1-[4-(乙基氨基)-1-哌啶基]乙酮 | 88535-88-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-[4-(乙基氨基)-1-哌啶基]乙酮
• 中文别名: N-乙酰基-4-乙胺基哌啶
• 英文名称: 1-(4-(Ethylamino)piperidin-1-YL)ethanone
• 英文别名: 1-[4-(ethylamino)piperidin-1-yl]ethanone
• CAS: 88535-88-0
• 化学式: C₉H₁₈N₂O
• mdl: MFCD12146367
• 分子量: 170.25
• InChiKey: BULWAFPAQBXUSO-UHFFFAOYSA-N

物化性质

• 密度：
  0.99

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

文献信息

• [EN] HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLES SERVANT D'INHIBITEURS D'IRAK, ET LEURS UTILISATIONS
  申请人：MERCK PATENT GMBH

  公开号：WO2016081679A1

  公开（公告）日：2016-05-26

  The present invention relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, useful as IRAK inhibitors.

  本发明涉及式I化合物或其药用可接受盐，用作IRAK抑制剂。
• [EN] INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS<br/>[FR] INHIBITEURS D'INTERACTIONS DE PROTÉINE EFFECTRICE RAS
  申请人：UNIV OXFORD INNOVATION LTD

  公开号：WO2019145719A1

  公开（公告）日：2019-08-01

  The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.

  本发明涉及本文中定义的式I化合物，以及其盐和溶剂合物。本发明还涉及包含式(I)化合物的药物组合物，以及用于治疗增殖性疾病（如癌症）以及其他疾病或情况的式(I)化合物，其中抑制RAS-效应蛋白-蛋白相互作用被认为是相关的。
• BUFADIENOLIDE DERIVATIVES, PREPARING PROCESS THEREOF, COMPOSITION COMPRISING THE SAME AND THE USE THEREOF
  申请人：Hu Lihong

  公开号：US20130005696A1

  公开（公告）日：2013-01-03

  The present invention provides a class of bufadienolide derivatives representing by the following formula I or pharmaceutically acceptable salts thereof, the preparing process thereof, pharmaceutical composition comprising the same and the use thereof. The bufadienolide derivatives have inhibitory activities against human-derived tumor cell lines, and thus can be used as a drug for treating malignancies.

  本发明提供了一类以以下公式I表示的蟾毒甾醇衍生物或其药用盐，其制备方法，包含相同的药物组合物以及其用途。蟾毒甾醇衍生物对人源肿瘤细胞系具有抑制活性，因此可用作治疗恶性肿瘤的药物。
• Benzene, Pyridine, and Pyridazine Derivatives
  申请人：Huang Kenneth He

  公开号：US20080096887A1

  公开（公告）日：2008-04-24

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , n, Q 1 , Q 2 , Q 3 , Y, and X 1 -X 4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明公开了式I的化合物和药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、n、Q1、Q2、Q3、Y和X1-X4的定义如本文所述。式I的化合物可用于治疗与细胞增殖有关的疾病和/或疾病，例如癌症、炎症、关节炎、血管生成或类似疾病。本发明还公开了包含本发明化合物的制药组合物和使用这些化合物治疗上述疾病的方法。
• BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES
  申请人：Huang Kenneth He

  公开号：US20110034529A1

  公开（公告）日：2011-02-10

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , n, Q 1 , Q 2 , Q 3 , Y, and X 1 -X 4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明公开了I式化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、n、Q1、Q2、Q3、Y和X1-X4如所定义。I式化合物在治疗与细胞增殖相关的疾病和/或病情，如癌症、炎症、关节炎、血管生成等方面具有用途。本发明还公开了包含本发明化合物的药物组合物及使用这些化合物治疗上述疾病的方法。